Literature DB >> 28986009

Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease.

Koji Sawada1.   

Abstract

Inflammatory bowel disease (IBD) like Crohn's disease and ulcerative colitis are chronic inflammatory disorders that affect the bowel. The disease is characterized by periods of clinical remission and relapse due to severe intestinal inflammation. Drug therapy of IBD is associated with unpleasant side effects. Further, efficacies of conventional drugs decrease with chronic use and this can represent a major difficulty in the long term management of IBD. However, in active IBD, leukocytes are elevated in the lesion they may be able to be a factor of IBD aggravation. Membrane filters column and leukocyte adsorbing beads have been developed which are direct blood perfusion systems for removing any desired level of leukocytes. Clinical studies with these two new models have shown good effects for active IBD. Clinical data suggest that leukocytapheresis might be an effective adjunct to therapy of IBD, to promote remission, taper conventional drug dosage and potentially should reduce the number of patients who require colectomy. The results may further understandings of the pathophysiology of IBD and this in turn should contribute to a more effective treatment of this disorder.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crohn's disease; Cytapheresis; Cytokine; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Year:  2017        PMID: 28986009     DOI: 10.1016/j.transci.2017.08.016

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  1 in total

Review 1.  Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease.

Authors:  Farah Yasmin; Hala Najeeb; Unaiza Naeem; Abdul Moeed; Thoyaja Koritala; Salim Surani
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.